The Iron Deficiency Anemia Therapy
market is expanding steadily due to rising global prevalence of anemia and increasing healthcare access. The market was valued at USD 8.6 billion in 2023, up from USD 8.0 billion in 2022, reflecting a 7.5% year-over-year (YoY) growth. Growing awareness, improved diagnostics, and expanding treatment options are significantly driving demand.
Historically, the Iron Deficiency Anemia Therapy market has shown consistent growth. In 2018, the market size stood at USD 5.9 billion, increasing to USD 6.3 billion in 2019 and USD 6.8 billion in 2020. It reached USD 7.4 billion in 2021 and USD 8.0 billion in 2022, marking a 45.8% increase between 2018 and 2023.
The Iron Deficiency Anemia Therapy market is projected to grow at a CAGR of 7.5% from 2024 to 2032, reaching approximately USD 14.8 billion by 2032. Increasing prevalence among women and children is expected to generate over USD 6 billion in incremental revenue during the forecast period.
Rising Prevalence Drives Treatment Demand
Globally, over 1.9 billion people were affected by anemia in 2023, with iron deficiency accounting for nearly 50% of cases. The prevalence increased by 4.2% YoY, particularly in developing regions.
Among women of reproductive age, anemia prevalence reached 29.6% in 2023, compared to 27.8% in 2018. Pediatric anemia cases increased by 5.1% YoY, with over 320 million children affected globally. These trends are significantly boosting the Iron Deficiency Anemia Therapy market demand.
Oral Iron Therapy Dominates with 62% Share
Oral iron supplements accounted for approximately 62% of the Iron Deficiency Anemia Therapy market in 2023, generating over USD 5.3 billion in revenue. These therapies remain the first-line treatment due to cost-effectiveness and ease of administration.
Prescription rates for oral iron increased by 6.8% YoY in 2023. However, intravenous (IV) iron therapies are gaining traction, growing at 9.2% annually due to faster efficacy and better patient compliance in severe cases.
Intravenous Iron Therapy Expands Rapidly
Intravenous iron therapy contributed approximately USD 2.6 billion to the Iron Deficiency Anemia Therapy market in 2023. IV iron usage increased by 10.4% YoY, particularly in hospital settings.
Over 18 million IV iron treatments were administered globally in 2023, compared to 14.5 million in 2019, marking a 24.1% increase. This segment is expected to grow at a CAGR of 8.9% through 2032, driven by rising chronic disease cases.
Regional Insights: Asia-Pacific Leads with 39% Share
Asia-Pacific dominated the Iron Deficiency Anemia Therapy market in 2023, accounting for 39% of global revenue. India and China together contributed over USD 2.7 billion, driven by high anemia prevalence.
India alone reported anemia prevalence of over 52% among women in 2023. Government healthcare programs allocated approximately USD 1.3 billion annually toward anemia prevention and treatment initiatives.
North America held a 28% market share, with the U.S. generating USD 2.2 billion in revenue in 2023. Europe accounted for 24%, led by Germany, the UK, and France.
Government Initiatives and Healthcare Spending
Global healthcare expenditure reached USD 9.8 trillion in 2023, growing at 5.6% annually. Governments increased funding for nutritional programs by 7.4% YoY to combat anemia.
India’s National Iron Plus Initiative targets over 300 million beneficiaries annually. Similarly, African nations increased healthcare budgets by 8.2% YoY, focusing on maternal and child health.
Public health campaigns improved diagnosis rates by 12% globally, leading to higher adoption of Iron Deficiency Anemia Therapy.
Production and Supply Chain Insights
Global production of iron supplements reached approximately 14.2 billion units in 2023, up from 13.1 billion units in 2022, reflecting an 8.4% YoY increase. Pharmaceutical manufacturing capacity utilization improved to 85%.
Raw material costs for iron compounds increased by 4.9% YoY, impacting production costs. However, large-scale manufacturing reduced average unit costs by 3.1%, making therapies more accessible.
Export volumes of iron supplements increased by 6.7% YoY, with Asia-Pacific accounting for over 57% of global supply.
Competitive Landscape and Industry Statistics
The top five companies in the Iron Deficiency Anemia Therapy market accounted for approximately 51% of total revenue in 2023. Leading players reported revenue growth between 6% and 10%, driven by expanding product portfolios.
R&D investments exceeded USD 780 million in 2023, focusing on improved formulations and combination therapies. New product launches increased by 9.5% YoY, enhancing treatment options.
Average treatment costs ranged between USD 25 and USD 180 per patient annually for oral therapies, while IV therapies ranged from USD 300 to USD 1,200.
Future Outlook and Market Forecast
The Iron Deficiency Anemia Therapy market is expected to add over USD 6.2 billion in incremental revenue between 2024 and 2032. Annual treatment volumes are projected to exceed 2.5 billion doses by 2030.
Increasing awareness programs are expected to reduce undiagnosed cases by 15% by 2030. IV therapy adoption is projected to reach 28% market share by 2032, up from 22% in 2023.
Asia-Pacific is expected to maintain dominance with over 41% market share by 2032, while Latin America and Africa are projected to grow at CAGRs of 8.1% and 8.5%, respectively.
Conclusion: Strong Growth Supported by Rising Healthcare Needs
The Iron Deficiency Anemia Therapy market is poised for steady expansion, growing from USD 5.9 billion in 2018 to an estimated USD 14.8 billion by 2032. With a CAGR of 7.5%, the market is driven by increasing prevalence and improved access to treatment.
Year-over-year growth consistently ranges between 7% and 9%, supported by rising production volumes and government initiatives. With over 2.5 billion projected treatment doses and continued innovation, the Iron Deficiency Anemia Therapy market will remain critical in global healthcare.
Read Full Research Study: https://marketintelo.com/report/iron-deficiency-anemia-therapy-market
Top comments (0)